The discovery of the drug candidate for Alzheimer’s disease, Huntington’s disease

Surprisingly, JM6 not penetrate into the brain, but inhibits KMO in the blood. Blood cells, and then send a protection signal to the brain in order to stabilize the function of brain cells and prevent neurodegeneration. The fact that the compound does not pass the so-called blood-brain barrier will facilitate testing in patients, such as the potential impact JM6 could be confirmed by a simple blood test.JM6 was named for the father of Dr. Muchowski, Dr. Joseph Muchowski, PhD, a retired chemical drug that has helped his son develop the new KMO inhibitor. The study was conducted in collaboration with the laboratories of Dr. Robert Schwarcz, University of Maryland School of Medicine professor and pioneer of the studies linking the enzyme KMO and metabolically related to the loss of nerve cells, and Professor Eliezer Masliah, University of California, San Diego, an expert in neuropathology

‘In a world where there are gaps, hope as Huntington’s disease, I am pleased that someone of the caliber of Mr. Muchowski suggested the possibility of upcoming clinical trials,’ said Charles Sabine former correspondent for NBC, which has seen the disease Huntington has killed his father. Both Mr. Sabine and his brother are currently in Huntington.’

The mice modeling Alzheimer’s disease, the new compound prevented memory deficits and loss of synaptic connections between brain cells – which are both key elements of human diseases. The mouse model of Huntington’s disease, inflammation of the brain prevented JM6 and loss of synaptic connections between brain cells, while extending the life span.

These conclusions are further strengthened by the research also published online in the journal Current Biology. Guided by Flaviano Giorgini, PhD, University of Leicester – and a former postdoc Dr. Muchowski – the study provides convincing evidence of the importance of other genetic and pharmacological KMO in fruit flies genetically altered to mimic Huntington’s disease.

The approach could provide a more effective and targeted for the treatment of toothache / anxiety, , migraine and other conditions, scientists say. clinic, Bob has written three books and edited two others.

The need for a novel treatment for brain diseases that degrade over time is great. Alzheimer’s disease – the most common – affecting about 5.4 million people in the U.S. alone, with an annual cost of $ 183 billion, according to the Alzheimer’s Association. Without an innovative treatment, the number of Americans with Alzheimer’s disease will double by 2050, as it develops a new case every 33 seconds. Huntington’s disease, meanwhile, is the most common neurodegenerative disease hereditary, which reduces the capacity of approximately 30,000 Americans to walk, talk and reason

Dr. Paul Muchowski, an investigator associated with Gladstone, specializes in neurodegenerative diseases.

It ‘also associate professor in the Department of Biochemistry and Biophysics and Neurology at the University of California, San Francisco .

This entry was posted in medicine. Bookmark the permalink.

Comments are closed.